Bristol shares plummeted 19%, or a loss of $24 billion in market value, in premarket trading on the Opdivo disappointment.
Merck's stock price shot up 11%, a gain of nearly $18 billion in market value, in reaction because the Opdivo setback is seen as a win for the company's competing checkpoint inhibitor Keytruda.
https://www.thestreet.com/story/13666312/1/bristol-myers-plunges-on-shocking-cancer-immunotherapy-lung-cancer-study-failure.html?puc=yahoo&cm_ven=YAHOO
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM